Breaking the Therapeutic Ceiling in Autoimmunity
We are building the world’s deepest Autoimmune Foundation Model, anchored by single-cell & spatial data matched with longitudinal clinical outcomes.
Supervised Representation Learning & Generative AI
At the core of ScaiVision™ is our proprietary Supervised Representation Learning method. This unbiased, cluster-free approach identifies complex molecular patterns associated with clinical outcomes without needing pre-defined cell types. This allows us to discover novel biological signals at unprecedented resolution and sensitivity, and subsequently to translate these discoveries into clinical assets.
With our new focus on autoimmune diseases, we have expanded our AI platform by training and refining Deep Generative and Single-Cell Foundation Models on vast amounts of patient-derived single-cell and spatial omics data. These powerful data models enable predictive disease modeling and patient endotyping at scale.
Our IBD Flagship Program
3.6mln
Single-cell profiles
500+
patients
1000+
samples
Breaking the Therapeutic Ceiling
Despite the rise of biologic disease-modifying drugs, a profound therapeutic ceiling persists in Inflammatory Bowel Disease (IBD). Primary non-response rates reach as high as 41% in Ulcerative Colitis (UC) and Crohn's Disease (CD), and nearly 70% of all IBD patients fail to achieve durable remission with first-line biologics.
Traditional R&D has hit a wall because it relies on bulk data that obscures the cellular heterogeneity driving treatment resistance. Scailyte’s IBD Flagship Program decodes this complexity through advanced patient endotyping, providing pharma partners with the high-resolution map needed to navigate the immunology market which is evolving towards high-efficacy precision treatments.
Strategic Avenues for Pharma Partnerships
We invite R&D teams to leverage our platform to maximize the value of their immunology portfolios through three key collaborative pillars:
SWISSIBDcohort
